Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.58 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.58 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | SYK | P43405 | 2/20 | 0.52 |
| ▸ | IKBKB | O14920 | 3/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.49 |
| ▸ | GSK3B | P49841 | 3/20 | 0.49 |
| ▸ | CDK2 | P24941 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | JAK2 | O60674 | 2/20 | 0.49 |
| ▸ | CDK4 | P11802 | 2/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | AURKA | O14965 | 2/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28499240 | 0.85 | KCNH2 (0.48) | KCNH2SCN5ASCN9AMEN1KMT2A | |
| SCHEMBL2296305 | 0.83 | KCNH2 (0.42) | KCNH2SCN5ASCN9AMEN1KMT2A | |
| SCHEMBL249084 | 0.81 | SYK (0.49) | KCNH2SCN5ASCN9ASYKCYP2C19 | |
| SCHEMBL2864184 | 0.81 | CYP2C19 (0.56) | KCNH2SCN5ASCN9AMEN1KMT2A | |
| SCHEMBL13713315 | 0.81 | KCNH2 (0.58) | KCNH2SCN5ASCN9AMEN1KMT2A | |
| SCHEMBL867999 | 0.81 | KCNH2 (0.58) | KCNH2SCN5ASCN9AMEN1KMT2A | |
| SCHEMBL3697392 | 0.81 | KCNH2 (0.58) | KCNH2SCN5ASCN9AMEN1KMT2A | |
| SCHEMBL10177401 | 0.81 | SCN9A (0.84) | KCNH2SCN5ASCN9AMEN1KMT2A | |
| SCHEMBL18656973 | 0.80 | KCNH2 (0.54) | KCNH2SCN5ASCN9AMEN1KMT2A | |
| SCHEMBL1741981 | 0.79 | KCNH2 (0.55) | KCNH2SCN5ASCN9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2702044-B1 | PROCESS FOR RILPIVIRINE | HETERO RESEARCH FOUNDATION (IN) | 2017-03-22 | — | — | EP | claimed |
| US-20140228385-A1 | PROCESS FOR RILPIVIRINE | HETERO RESEARCH FOUNDATION (IN) | 2014-08-14 | — | — | US | claimed |
| EP-2702044-A2 | PROCESS FOR RILPIVIRINE | Hetero Research Foundation (IN) | 2014-03-05 | — | — | EP | claimed |
| WO-2012147091-A2 | PROCESS FOR RILPIVIRINE | HETERO RESEARCH FOUNDATION (IN) | 2012-11-01 | — | — | WO | claimed |
| CN-116675649-A | Novel process for efficiently and safely synthesizing rilpivirine intermediate | 中科苏州药物研究院 | 2023-09-01 | — | — | CN | disclosed |
| EP-2755959-B1 | RILPIVIRINE HYDROCHLORIDE | HETERO RESEARCH FOUNDATION (IN) | 2018-05-16 | — | — | EP | disclosed |
| EP-2702044-B1 | PROCESS FOR RILPIVIRINE | HETERO RESEARCH FOUNDATION (IN) | 2017-03-22 | — | — | EP | disclosed |
| EP-2643294-B1 | AN IMPROVED RILPIVIRINE PROCESS | EMCURE PHARMACEUTICALS LTD (IN) | 2016-08-24 | — | — | EP | disclosed |
| EP-2643294-B1 | AN IMPROVED RILPIVIRINE PROCESS | EMCURE PHARMACEUTICALS LTD (IN) | 2016-08-24 | — | — | EP | disclosed |
| US-9233935-B2 | Rilpivirine hydrochloride | HETERO RESEARCH FOUNDATION (IN) | 2016-01-12 | — | — | US | disclosed |
| US-9126949-B2 | Process for rilpivirine | HETERO RESEARCH FOUNDATION (IN) | 2015-09-08 | — | — | US | disclosed |
| US-9126949-B2 | Process for rilpivirine | HETERO RESEARCH FOUNDATION (IN) | 2015-09-08 | — | — | US | disclosed |
| US-20110152303-A1 | Chemical Compounds | GLAXOSMITHKLINE LLC (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110152303-A1 | Chemical Compounds | GLAXOSMITHKLINE LLC (US) | 2011-06-23 | — | — | US | disclosed |
| US-7514445-B2 | Heteroaryl amines as glycogen synthase kinase 3β inhibitors (GSK3 inhibitors) | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-07 | — | — | US | disclosed |
| US-20080171878-A1 | Process for Preparing 4-[(1,6-Dihydro-6-Oxo-2-Pyrimidinyl)Amino]Benzonitrile | JANSSEN SCIENCES IRELAND UC (IE) | 2008-07-17 | — | — | US | disclosed |
| US-20080171878-A1 | Process for Preparing 4-[(1,6-Dihydro-6-Oxo-2-Pyrimidinyl)Amino]Benzonitrile | JANSSEN SCIENCES IRELAND UC (IE) | 2008-07-17 | — | — | US | disclosed |
| US-20050004125-A1 | Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors) | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-06 | — | — | US | disclosed |
| EP-1448556-A1 | HETEROARYL AMINES AS GLYCOGEN SYNTHASE KINASE 3BETA INHIBITORS (GSK3 INHIBITORS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003037891-A1 | HETEROARYL AMINES AS GLYCOGEN SYNTHASE KINASE 3BETA INHIBITORS (GSK3 INHIBITORS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171878-A1 | Process for Preparing 4-[(1,6-Dihydro-6-Oxo-2-Pyrimidinyl)Amino]Benzonitrile | ME1, ALKBH1, DPYD | KCNH2 985/4885SCN5A 2879/4885SCN9A 2721/4885 |
| US-20110152303-A1 | Chemical Compounds | TYMP, SAMHD1, DPYD | KCNH2 2986/4885SCN5A 3811/4885SCN9A 3231/4885 |
| US-20140228385-A1 | PROCESS FOR RILPIVIRINE | SAMHD1, EIF2AK2, IL4 | KCNH2 2546/4885SCN5A 1853/4885SCN9A 3784/4885 |
| US-20050004125-A1 | Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors) | GSK3B, GSK3A, GSKIP | KCNH2 987/4885SCN5A 839/4885SCN9A 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.